LMGF(SZ:002734) Ge Long Hui A P P·2025-08-14 11:30Core Viewpoint - The company reported significant growth in both revenue and net profit for the first half of the year, indicating improved profitability and operational efficiency [1] Financial Performance - The company achieved a revenue of 2.452 billion yuan, representing a year-on-year increase of 6.69% [1] - The net profit attributable to shareholders reached 269 million yuan, showing a remarkable year-on-year growth of 747.13% [1] - The company's asset-liability ratio has significantly decreased, reflecting enhanced financial stability [1] Research and Development - The company's technical research and development capabilities are continuously strengthening, with steady progress in the chemical synthesis creation plan [1] - Collaboration with multinational companies on innovative drug development is advancing smoothly [1] - The product planning framework is progressively forming, and the level of formulation research is consistently improving [1] - Research in biological synthesis is being solidly developed [1] Market and Brand Development - Domestic and international market channels are becoming increasingly mature, with comprehensive deepening of brand building [1] Operational Efficiency - The management of production bases has undergone iterative upgrades, resulting in significant improvements in overall efficiency [1] - The effects of business process reengineering within the group are notable, leading to more efficient operational quality [1] Social Responsibility - The company is further demonstrating its social responsibility, with a solid foundation for safety and environmental protection [1]